Literature DB >> 30714660

Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction.

Rodolfo Citro1, Ilaria Radano1, Guido Parodi2, Davide Di Vece1,3, Concetta Zito4, Giuseppina Novo5, Gennaro Provenza1, Michele Bellino1, Costantina Prota1, Angelo Silverio1, Francesco Antonini-Canterin6, Fausto Rigo7, Olga Vriz8, Gennaro Galasso1, Eduardo Bossone1, Jorge Salerno-Uriarte9, Federico Piscione1.   

Abstract

AIM: To evaluate the long-term outcome of patients with Takotsubo syndrome (TTS) and severely reduced left ventricular ejection fraction (LVEF ≤ 35%) at presentation. METHODS AND
RESULTS: The study population included 326 patients (mean age 69.5 ± 10.7 years, 28 male) with TTS enrolled in the Takotsubo Italian Network, divided into two groups according to LVEF (≤ 35%, n = 131; > 35%, n = 195), as assessed by transthoracic echocardiography at hospital admission. In-hospital events were recorded in both groups. At long-term follow-up (median 26.5 months, interquartile range 18-33), composite major adverse cardiac events (MACE: cardiac death, acute myocardial infarction, heart failure, and TTS recurrence) and rehospitalization were investigated. Compared to patients with LVEF > 35%, patients with LVEF ≤ 35% were older (71.2 ± 10.8 vs. 68.4 ± 10.6 years; P = 0.026) and experienced more frequently cardiogenic shock (16% vs. 4.6%; P < 0.001), acute heart failure (28.2% vs. 12.8%; P = 0.001), and intra-aortic balloon pump support (11.5% vs. 2.6%; P = 0.001) in the acute phase. At long-term follow-up, higher rates of composite MACE (25.2% vs. 10.8%; P = 0.001) and rehospitalization for cardiac causes (26% vs. 13.3%; P = 0.004) were observed in these patients. LVEF ≤ 35% at admission [hazard ratio (HR) 2.184, 95% confidence interval (CI) 1.231-3.872; P = 0.008] and age (HR 1.041, 95% CI 1.011-1.073; P = 0.006) were independent predictors of MACE. Patients with LVEF ≤ 35% also had a significant lower freedom from composite MACE during long-term follow-up (χ2 = 11.551, P = 0.001).
CONCLUSION: Left ventricular ejection fraction ≤ 35% at presentation is a key parameter to identify TTS patients at higher risk not only in the acute phase but also at long-term follow-up.
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

Entities:  

Keywords:  Cardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndrome

Mesh:

Year:  2019        PMID: 30714660     DOI: 10.1002/ejhf.1373

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  12 in total

1.  Association Between Mortality and Left Ventricular Ejection Fraction in Patients With Takotsubo Syndrome Versus Acute Coronary Syndrome.

Authors:  Mohammad Abumayyaleh; Ibrahim El-Battrawy; Marvin Kummer; Thorsten Gietzen; Michael Behnes; Xiao-Bo Zhou; Siegfried Lang; Martin Borggrefe; Ibrahim Akin
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome.

Authors:  Marvin Kummer; Ibrahim El-Battrawy; Thorsten Gietzen; Uzair Ansari; Michael Behnes; Siegfried Lang; Xiaobo Zhou; Martin Borggrefe; Ibrahim Akin
Journal:  Front Pharmacol       Date:  2020-05-14       Impact factor: 5.810

Review 3.  Takotsubo syndrome in Heart Failure and World Congress on Acute Heart Failure 2019: highlights from the experts.

Authors:  Kalliopi Keramida; Johannes Backs; Eduardo Bossone; Rodolfo Citro; Dana Dawson; Elmir Omerovic; Guido Parodi; Birke Schneider; Jelena R Ghadri; Linda W Van Laake; Alexander R Lyon
Journal:  ESC Heart Fail       Date:  2020-01-29

4.  Multimodality imaging in takotsubo syndrome: a joint consensus document of the European Association of Cardiovascular Imaging (EACVI) and the Japanese Society of Echocardiography (JSE).

Authors:  Rodolfo Citro; Hiroyuki Okura; Jelena R Ghadri; Chisato Izumi; Patrick Meimoun; Masaki Izumo; Dana Dawson; Shuichiro Kaji; Ingo Eitel; Nobuyuki Kagiyama; Yukari Kobayashi; Christian Templin; Victoria Delgado; Satoshi Nakatani; Bogdan A Popescu
Journal:  J Echocardiogr       Date:  2020-09-04

5.  Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry.

Authors:  Ken Kato; Victoria L Cammann; L Christian Napp; Konrad A Szawan; Jozef Micek; Sara Dreiding; Rena A Levinson; Vanya Petkova; Michael Würdinger; Alexandru Patrascu; Rafael Sumalinog; Sebastiano Gili; Christian F Clarenbach; Malcolm Kohler; Manfred Wischnewsky; Rodolfo Citro; Carmine Vecchione; Eduardo Bossone; Michael Neuhaus; Jennifer Franke; Benjamin Meder; Milosz Jaguszewski; Michel Noutsias; Maike Knorr; Susanne Heiner; Fabrizio D'Ascenzo; Wolfgang Dichtl; Christof Burgdorf; Behrouz Kherad; Carsten Tschöpe; Annahita Sarcon; Jerold Shinbane; Lawrence Rajan; Guido Michels; Roman Pfister; Alessandro Cuneo; Claudius Jacobshagen; Mahir Karakas; Wolfgang Koenig; Alexander Pott; Philippe Meyer; Marco Roffi; Adrian Banning; Mathias Wolfrum; Florim Cuculi; Richard Kobza; Thomas A Fischer; Tuija Vasankari; K E Juhani Airaksinen; Monika Budnik; Rafal Dworakowski; Philip MacCarthy; Christoph Kaiser; Stefan Osswald; Leonarda Galiuto; Christina Chan; Paul Bridgman; Daniel Beug; Clément Delmas; Olivier Lairez; Ekaterina Gilyarova; Alexandra Shilova; Mikhail Gilyarov; Ibrahim El-Battrawy; Ibrahim Akin; Martin Kozel; Petr Tousek; David E Winchester; Jan Galuszka; Christian Ukena; Gregor Poglajen; Pedro Carrilho-Ferreira; Christian Hauck; Carla Paolini; Claudio Bilato; Masanori Sano; Iwao Ishibashi; Masayuki Takahara; Toshiharu Himi; Yoshio Kobayashi; Abhiram Prasad; Charanjit S Rihal; Kan Liu; P Christian Schulze; Matteo Bianco; Lucas Jörg; Hans Rickli; Gonçalo Pestana; Thanh H Nguyen; Michael Böhm; Lars S Maier; Fausto J Pinto; Petr Widimský; Stephan B Felix; Grzegorz Opolski; Ruediger C Braun-Dullaeus; Wolfgang Rottbauer; Gerd Hasenfuß; Burkert M Pieske; Heribert Schunkert; Martin Borggrefe; Holger Thiele; Johann Bauersachs; Hugo A Katus; John D Horowitz; Carlo Di Mario; Thomas Münzel; Filippo Crea; Jeroen J Bax; Thomas F Lüscher; Frank Ruschitzka; Jelena R Ghadri; Christian Templin
Journal:  ESC Heart Fail       Date:  2021-03-13

6.  A case report of takotsubo syndrome complicated by ischaemic stroke: the clinical dilemma of anticoagulation.

Authors:  Giuseppe Iuliano; Rosa Napoletano; Carmine Vecchione; Rodolfo Citro
Journal:  Eur Heart J Case Rep       Date:  2021-03-15

Review 7.  Impact of right ventricular impairment on morbidity and mortality in takotsubo syndrome-a meta-analysis of observational trials.

Authors:  Suchith Shetty; Aaqib H Malik; Manju Bengaluru Jayanna; Wilbert S Aronow; Alexandros Briasoulis; Kan Liu
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

8.  Characteristics and Outcomes of Patients With Takotsubo Syndrome: Incremental Prognostic Value of Baseline Left Ventricular Systolic Function.

Authors:  Alaa Alashi; Nicolas Isaza; Jackson Faulx; Zoran B Popovic; Venu Menon; Stephen G Ellis; Michael Faulx; Samir R Kapadia; Brian P Griffin; Milind Y Desai
Journal:  J Am Heart Assoc       Date:  2020-08-05       Impact factor: 5.501

9.  Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry.

Authors:  Luca Arcari; Maria Beatrice Musumeci; Thomas Stiermaier; Ibrahim El-Battrawy; Christian Möller; Federico Guerra; Giuseppina Novo; Enrica Mariano; Luca Rosario Limite; Luca Cacciotti; Raffaella Semeraro; Massimo Volpe; Francesco Romeo; Pasquale Caldarola; Holger Thiele; Ibrahim Akin; Natale Daniele Brunetti; Ingo Eitel; Francesco Santoro
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

Review 10.  A systematic review on focal takotsubo syndrome: a not-so-small matter.

Authors:  Giacomo Tini; Luca Rosario Limite; Luca Arcari; Luca Cacciotti; Domitilla Russo; Matteo Sclafani; Claudio Brunelli; Massimo Volpe; Camillo Autore; Maria Beatrice Musumeci
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.